Company intelligence / Profile preview

Genewity

Leiden, South Holland, Netherlandsgenewity.tech ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Genewity is developing advanced autologous gene-modified cell therapies to restore immune function in patients with severe immune disorders. The company leverages lentiviral vector technology to generate thymus cells from pluripotent stem cells, targeting conditions such as congenital athymia and autoimmune diseases. It holds multiple licenses from Dutch University Medical Centers and is engaged in both research programs and at least one clinical trial.

Therapeutic areas: Immunology
Modalities: Gene therapyCell therapyAutologous gene-modified cell therapyLentiviral vector-based gene modification
Industry: Biotech

Partnerships

Leiden University Medical Center (LUMC)Dutch University Medical Centers

Beyond the preview

Go deeper on Genewity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genewity.

Explore the full profile